| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Zebrafish | 15 | 2025 | 96 | 4.660 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 8 | 2020 | 13 | 3.170 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2021 | 8 | 2.340 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2018 | 44 | 1.490 |
Why?
|
| B-Lymphocytes | 3 | 2024 | 285 | 1.460 |
Why?
|
| Animals, Genetically Modified | 9 | 2025 | 54 | 1.200 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2018 | 120 | 1.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2018 | 414 | 0.880 |
Why?
|
| Thymus Gland | 1 | 2024 | 54 | 0.850 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2018 | 16 | 0.800 |
Why?
|
| Cell Lineage | 2 | 2019 | 51 | 0.740 |
Why?
|
| Lymphoma, B-Cell | 2 | 2018 | 19 | 0.690 |
Why?
|
| Green Fluorescent Proteins | 2 | 2019 | 101 | 0.670 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2018 | 465 | 0.660 |
Why?
|
| Neoplasms, Experimental | 2 | 2019 | 58 | 0.640 |
Why?
|
| Hypertriglyceridemia | 1 | 2019 | 8 | 0.630 |
Why?
|
| Animals | 15 | 2025 | 10580 | 0.610 |
Why?
|
| Dyslipidemias | 1 | 2019 | 32 | 0.610 |
Why?
|
| Cell Separation | 1 | 2019 | 55 | 0.600 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 117 | 0.590 |
Why?
|
| Lymphopoiesis | 1 | 2018 | 22 | 0.580 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2021 | 42 | 0.580 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2018 | 26 | 0.580 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 163 | 0.560 |
Why?
|
| T-Lymphocytes | 4 | 2024 | 285 | 0.540 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 550 | 0.520 |
Why?
|
| Databases, Factual | 1 | 2017 | 265 | 0.490 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 27 | 0.480 |
Why?
|
| Humans | 21 | 2024 | 28581 | 0.460 |
Why?
|
| Microsporida | 1 | 2014 | 1 | 0.440 |
Why?
|
| Fish Diseases | 1 | 2014 | 4 | 0.440 |
Why?
|
| Microsporidiosis | 1 | 2014 | 4 | 0.430 |
Why?
|
| Granuloma | 1 | 2014 | 18 | 0.430 |
Why?
|
| Cell Line, Tumor | 2 | 2017 | 1338 | 0.420 |
Why?
|
| Necrosis | 1 | 2014 | 85 | 0.420 |
Why?
|
| Translocation, Genetic | 2 | 2011 | 23 | 0.410 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2020 | 21 | 0.390 |
Why?
|
| Burkitt Lymphoma | 3 | 2018 | 4 | 0.380 |
Why?
|
| Genomics | 2 | 2020 | 123 | 0.370 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 671 | 0.370 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2011 | 2 | 0.350 |
Why?
|
| Cell Differentiation | 3 | 2024 | 419 | 0.320 |
Why?
|
| Transgenes | 1 | 2009 | 63 | 0.300 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2020 | 140 | 0.250 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 194 | 0.250 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 453 | 0.250 |
Why?
|
| Child | 6 | 2021 | 2271 | 0.240 |
Why?
|
| Lymphoid Tissue | 1 | 2025 | 9 | 0.230 |
Why?
|
| Lymphatic Vessels | 1 | 2025 | 22 | 0.230 |
Why?
|
| Disease Models, Animal | 2 | 2012 | 1494 | 0.220 |
Why?
|
| Lymphocytes | 1 | 2024 | 90 | 0.210 |
Why?
|
| Biopsy | 1 | 2024 | 207 | 0.210 |
Why?
|
| Models, Animal | 1 | 2024 | 130 | 0.210 |
Why?
|
| Male | 8 | 2021 | 13771 | 0.210 |
Why?
|
| Incidence | 2 | 2019 | 568 | 0.200 |
Why?
|
| Phenotype | 2 | 2019 | 682 | 0.200 |
Why?
|
| Child, Preschool | 4 | 2016 | 1167 | 0.190 |
Why?
|
| Adolescent | 4 | 2018 | 3165 | 0.190 |
Why?
|
| Rituximab | 2 | 2018 | 64 | 0.170 |
Why?
|
| Female | 7 | 2021 | 15471 | 0.170 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2020 | 3 | 0.170 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 79 | 0.160 |
Why?
|
| Pedigree | 1 | 2019 | 155 | 0.150 |
Why?
|
| India | 1 | 2019 | 143 | 0.150 |
Why?
|
| Immunotherapy | 2 | 2018 | 160 | 0.150 |
Why?
|
| Flow Cytometry | 2 | 2011 | 291 | 0.150 |
Why?
|
| Genetic Testing | 1 | 2019 | 68 | 0.150 |
Why?
|
| Injections, Spinal | 1 | 2018 | 7 | 0.150 |
Why?
|
| Consolidation Chemotherapy | 2 | 2015 | 2 | 0.140 |
Why?
|
| Diet, High-Fat | 1 | 2019 | 137 | 0.140 |
Why?
|
| Prognosis | 2 | 2021 | 807 | 0.140 |
Why?
|
| Web Browser | 1 | 2017 | 4 | 0.140 |
Why?
|
| Case-Control Studies | 1 | 2019 | 732 | 0.130 |
Why?
|
| Antineoplastic Agents | 2 | 2013 | 681 | 0.130 |
Why?
|
| Leukemia, T-Cell | 1 | 2016 | 2 | 0.120 |
Why?
|
| Leukemia, B-Cell | 1 | 2016 | 3 | 0.120 |
Why?
|
| Molecular Biology | 1 | 2016 | 17 | 0.120 |
Why?
|
| Mutation | 1 | 2019 | 864 | 0.120 |
Why?
|
| Cytarabine | 2 | 2014 | 4 | 0.120 |
Why?
|
| Vincristine | 2 | 2014 | 9 | 0.120 |
Why?
|
| Methotrexate | 2 | 2014 | 36 | 0.110 |
Why?
|
| Prednisone | 2 | 2014 | 53 | 0.110 |
Why?
|
| Cyclophosphamide | 2 | 2014 | 41 | 0.110 |
Why?
|
| Doxorubicin | 2 | 2014 | 77 | 0.110 |
Why?
|
| Pyrazoles | 2 | 2013 | 70 | 0.110 |
Why?
|
| United States | 2 | 2019 | 2201 | 0.110 |
Why?
|
| Biomarkers | 1 | 2017 | 770 | 0.100 |
Why?
|
| Immunoglobulin Light Chains, Surrogate | 1 | 2013 | 1 | 0.100 |
Why?
|
| Rhabdoid Tumor | 1 | 2013 | 9 | 0.100 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2013 | 3 | 0.100 |
Why?
|
| Teratoma | 1 | 2013 | 17 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 270 | 0.100 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 163 | 0.100 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2013 | 51 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 1 | 2013 | 95 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2013 | 128 | 0.100 |
Why?
|
| Hydrazones | 1 | 2012 | 3 | 0.090 |
Why?
|
| Quinolines | 1 | 2012 | 26 | 0.090 |
Why?
|
| Leukemia | 1 | 2012 | 30 | 0.090 |
Why?
|
| Treatment Outcome | 1 | 2018 | 2402 | 0.090 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 60 | 0.090 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2011 | 6 | 0.090 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 90 | 0.090 |
Why?
|
| Genome | 1 | 2011 | 56 | 0.090 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2010 | 22 | 0.080 |
Why?
|
| Zebrafish Proteins | 1 | 2010 | 20 | 0.080 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 638 | 0.080 |
Why?
|
| Mutagenesis | 1 | 2009 | 46 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 66 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 328 | 0.070 |
Why?
|
| Young Adult | 1 | 2016 | 2804 | 0.070 |
Why?
|
| Middle Aged | 1 | 2019 | 7310 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2009 | 667 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2006 | 4 | 0.060 |
Why?
|
| Chromosome Deletion | 1 | 2006 | 15 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2006 | 13 | 0.060 |
Why?
|
| Axilla | 1 | 2025 | 2 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2025 | 103 | 0.060 |
Why?
|
| Dipyrone | 1 | 2002 | 1 | 0.050 |
Why?
|
| Pyrazolones | 1 | 2002 | 1 | 0.050 |
Why?
|
| Medicine, Traditional | 1 | 2002 | 10 | 0.050 |
Why?
|
| Emigration and Immigration | 1 | 2002 | 9 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2013 | 155 | 0.050 |
Why?
|
| Ikaros Transcription Factor | 1 | 2021 | 9 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2002 | 78 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2013 | 581 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2021 | 120 | 0.040 |
Why?
|
| Gene Transfer Techniques | 1 | 2020 | 74 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2021 | 893 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 31 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 133 | 0.030 |
Why?
|
| Typhlitis | 1 | 2014 | 1 | 0.030 |
Why?
|
| Genes, myc | 1 | 2014 | 9 | 0.030 |
Why?
|
| Etoposide | 1 | 2014 | 19 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2014 | 18 | 0.030 |
Why?
|
| Remission Induction | 1 | 2014 | 58 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2014 | 102 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 42 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 224 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 236 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2014 | 81 | 0.030 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2013 | 10 | 0.030 |
Why?
|
| Jurkat Cells | 1 | 2013 | 30 | 0.030 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2013 | 13 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2015 | 458 | 0.030 |
Why?
|
| Blast Crisis | 1 | 2012 | 1 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 137 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 82 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2012 | 135 | 0.020 |
Why?
|
| Mitosis | 1 | 2012 | 115 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 274 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 475 | 0.020 |
Why?
|
| VDJ Exons | 1 | 2010 | 1 | 0.020 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2010 | 8 | 0.020 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2010 | 7 | 0.020 |
Why?
|
| Complementarity Determining Regions | 1 | 2010 | 11 | 0.020 |
Why?
|
| Apoptosis | 1 | 2012 | 777 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 344 | 0.020 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2006 | 4 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2006 | 75 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2006 | 25 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2012 | 1454 | 0.010 |
Why?
|
| Adult | 1 | 2015 | 7922 | 0.010 |
Why?
|
| Agranulocytosis | 1 | 2002 | 1 | 0.010 |
Why?
|
| Legislation, Drug | 1 | 2002 | 6 | 0.010 |
Why?
|
| Mice | 1 | 2012 | 4732 | 0.010 |
Why?
|
| Neutropenia | 1 | 2002 | 41 | 0.010 |
Why?
|
| Mexico | 1 | 2002 | 91 | 0.010 |
Why?
|
| Sepsis | 1 | 2002 | 86 | 0.010 |
Why?
|
| Pain | 1 | 2002 | 258 | 0.010 |
Why?
|